UBS Group
ALZN icon

UBS Group’s Alzamend Neuro ALZN Stock Holding History

UBS Group’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.82K Sell
2,352
-2,152
-48% -$2.39K ﹤0.01% 9287
2026
Q1 		$4.77K Sell
4,504
-20,063
-82% -$40.1K ﹤0.01% 8886
2025
Q4 		$44.7K Buy
24,567
+22,492
+1,084% +$51K ﹤0.01% 7288
2025
Q3 		$4.94K Buy
2,075
+1,173
+130% +$3.05K ﹤0.01% 8912
2025
Q2 		$2.63K Buy
+902
New +$4.47K ﹤0.01% 9436
2025
Q1 		– Sell
-91
Closed -$951 – 10186
2024
Q4 		$951 Buy
+91
New +$1.17K ﹤0.01% 9343
2024
Q3 		– Sell
-57
Closed -$2.02K – 9463
2024
Q2 		$2.02K Buy
+57
New +$3.26K ﹤0.01% 8439
2024
Q1 		– Sell
-21
Closed -$1.7K – 9248
2023
Q4 		$1.7K Buy
21
+15
+250% +$2.46K ﹤0.01% 8241
2023
Q3 		$1.88K Buy
+6
New +$2.87K ﹤0.01% 7809
2023
Q2 		– Sell
-2
Closed -$1.57K – 8462
2023
Q1 		$1.26K Sell
2
-5
-71% -$3.76K ﹤0.01% 8773
2022
Q4 		$5.22K Sell
7
-7
-50% -$10.1K ﹤0.01% 9205
2022
Q3 		$22K Sell
14
-1
-7% -$1.37K ﹤0.01% 7237
2022
Q2 		$18K Buy
15
+3
+25% +$3.89K ﹤0.01% 6986
2022
Q1 		$20K Buy
12
+10
+500% +$18.8K ﹤0.01% 7436
2021
Q4 		$5K Hold
2
– – ﹤0.01% 9369
2021
Q3 		$8K Hold
2
– – ﹤0.01% 8185
2021
Q2 		$24K Buy
+2
New +$25.8K ﹤0.01% 7131

Other funds holding ALZN

KCIA
Kingsbury Capital Investment Advisors Wilmette, Illinois $118M AUM
KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
IA
IFG Advisory Atlanta, Georgia $2.85B AUM 26.07% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

UBS Group's ALZN Position: Q2 2026 in Review

UBS Group reduced its Alzamend Neuro (ALZN) stake by 48% in Q2 2026, selling an estimated $2.39K and leaving 2,352 shares worth $2.82K. The position accounts for ﹤0.01% of the portfolio, ranked #9287.

UBS Group first reported a position in ALZN in Q2 2021 and has held it in 17 quarters since. The position peaked at $44.7K in Q4 2025. 12 funds tracked by Wall St. Rank hold ALZN as of Q2 2026.

  • UBS Group held 2,352 shares of Alzamend Neuro worth $2.82K as of Q2 2026.
  • UBS Group sold 2,152 Alzamend Neuro shares in Q2 2026, an estimated $2.39K.
  • Alzamend Neuro made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9287 holding.
  • UBS Group first reported a position in Alzamend Neuro in Q2 2021 and has held it in 17 quarters since.
  • UBS Group's Alzamend Neuro position peaked at $44.7K in Q4 2025.
  • 12 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.